Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray

BACKGROUND: Tourette syndrome (TS) manifests with motor and vocal tics that can reach disabling intensity. Established therapies may show insufficient relief or side effects. Cannabinoids have demonstrated therapeutic potential in small studies. This report presents buccal Nabiximols “as required” i...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwittay, Maximilian A., Steinbrecher, Andreas, Lobsien, Elmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344952/
https://www.ncbi.nlm.nih.gov/pubmed/34430070
http://dx.doi.org/10.5334/tohm.613
_version_ 1783734512524460032
author Schwittay, Maximilian A.
Steinbrecher, Andreas
Lobsien, Elmar
author_facet Schwittay, Maximilian A.
Steinbrecher, Andreas
Lobsien, Elmar
author_sort Schwittay, Maximilian A.
collection PubMed
description BACKGROUND: Tourette syndrome (TS) manifests with motor and vocal tics that can reach disabling intensity. Established therapies may show insufficient relief or side effects. Cannabinoids have demonstrated therapeutic potential in small studies. This report presents buccal Nabiximols “as required” in the treatment of tics in TS. CASE REPORT: A 25-year-old man presented with stigmatizing motor and phonic tics after cessation of daily Cannabis use. After Tiaprid 300 mg per day had shown no sufficient effect a trial of Nabiximols reduced tics by >90%. DISCUSSION: Nabiximols could be an adjunct treatment in TS for situations were tics are severly disabling.
format Online
Article
Text
id pubmed-8344952
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-83449522021-08-23 Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray Schwittay, Maximilian A. Steinbrecher, Andreas Lobsien, Elmar Tremor Other Hyperkinet Mov (N Y) Case Report BACKGROUND: Tourette syndrome (TS) manifests with motor and vocal tics that can reach disabling intensity. Established therapies may show insufficient relief or side effects. Cannabinoids have demonstrated therapeutic potential in small studies. This report presents buccal Nabiximols “as required” in the treatment of tics in TS. CASE REPORT: A 25-year-old man presented with stigmatizing motor and phonic tics after cessation of daily Cannabis use. After Tiaprid 300 mg per day had shown no sufficient effect a trial of Nabiximols reduced tics by >90%. DISCUSSION: Nabiximols could be an adjunct treatment in TS for situations were tics are severly disabling. Ubiquity Press 2021-08-06 /pmc/articles/PMC8344952/ /pubmed/34430070 http://dx.doi.org/10.5334/tohm.613 Text en Copyright: © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Case Report
Schwittay, Maximilian A.
Steinbrecher, Andreas
Lobsien, Elmar
Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
title Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
title_full Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
title_fullStr Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
title_full_unstemmed Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
title_short Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
title_sort tic reduction in adult onset gilles de la tourette syndrome using as required nabiximols spray
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344952/
https://www.ncbi.nlm.nih.gov/pubmed/34430070
http://dx.doi.org/10.5334/tohm.613
work_keys_str_mv AT schwittaymaximiliana ticreductioninadultonsetgillesdelatourettesyndromeusingasrequirednabiximolsspray
AT steinbrecherandreas ticreductioninadultonsetgillesdelatourettesyndromeusingasrequirednabiximolsspray
AT lobsienelmar ticreductioninadultonsetgillesdelatourettesyndromeusingasrequirednabiximolsspray

Ejemplares similares